Press Releases

BETHESDA, MD, September 12, 2023 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announces that Dr. Linda Liau, MD, PhD, MBA has joined the Company’s Scientific Advisory Board (SAB). Dr. Liau served as the Principal Investigator of the Phase 3 trial of DCVax®-L for treatment of glioblastoma. She is Chair of the Department of Neurosurgery at... Read More

For immediate release on August 29, 2023 BETHESDA, MD, August 29, 2023 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announces that it plans to submit a Marketing Authorization Application (MAA) in the U.K., to the Medicines and Healthcare Products Regulatory Agency (MHRA)(the equivalent of the U.S. FDA), for commercial approval of the... Read More

For Immediate Release on March 20, 2023 One of the First UK Licenses for Commercial Manufacturing of Cell Therapy Products; Allows Global Delivery of the Products BETHESDA, MD, March 20, 2023 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, and Advent BioServices, a leading contract development and manufacturing organization (CDMO) based in... Read More

78% Of All Shares Were Voted;  Proposals Received ≥90% of Votes Cast BETHESDA, MD, January 6, 2023 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported positive results of voting at the Annual Shareholders Meeting on December 30, 2022, and discussion at the Meeting (which was publicly available) about achievements in 2022 and... Read More

Both Median Survival and “Long Tail” of Extended Survival Were Increased In Both Newly Diagnosed and Recurrent Glioblastoma Results Featured In JAMA Oncology Peer Reviewed Publication BETHESDA, Md., November 17, 2022 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today reported that in its Phase III clinical trial both median survival and... Read More